GPT and Anorexia: Although liver enzymes were not elevated before the initiation of cabozantinib therapy, grade 3 increases in aspartate aminotransferase and alanine aminotransferase levels (386 IU/L and 105 IU/L, respectively) and anorexia, and grade 1 nausea and vomiting (according to the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) were observed 1 week after the start of cabozantinib treatment (Table 1).